Navigation Links
Amylin Issues Statement in Response to Carl Icahn
Date:4/23/2009

SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today issued the following statement from James N. Wilson, Lead Independent Director, on behalf of the Amylin Board of Directors:

The Amylin Board of Directors welcomes continued three-way dialogue with Carl Icahn and Eastbourne Capital Management, L.L.C. to find a path to end a proxy contest. We hope that we can reach a resolution that will be in the best interests of all Amylin shareholders.

About Amylin

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

This press release may be deemed to be solicitation material in respect of the matters to be considered at the 2009 Annual Meeting of Stockholders. Amylin has filed the definitive proxy statement with the Securities and Exchange Commission ("SEC") on April 20, 2009. INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE PROXY STATEMENT, THE BLUE PROXY CARD AND ANY OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors and securityholders may obtain the proxy statement and other relevant documents free of charge at the
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Icahn Asks Amylin to Allow Discussions With Eastbourne
2. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
3. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
4. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
5. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
6. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
7. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
8. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
9. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
10. Amylin Pharmaceuticals Reports Third Quarter Financial Results
11. Amylin Pharmaceuticals to Webcast Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Utah , July 10, 2014 /PRNewswire-iReach/ ... annotation and interpretation, today announced an agreement ... (NGS) analytics for Lineagen,s NextStep Dx ... of neurodevelopmental and neurological disorders, currently offers ... microarray (CMA) testing service used by healthcare ...
(Date:7/10/2014)... Calif., July 10, 2014   Ceres, Inc . ... seed company, announced today financial results for the three ... on its business. Ceres reported that the ... product performance this growing season in Brazil, which concluded ... the company,s sorghum evaluation areas for part of the ...
(Date:7/10/2014)... of Adelaide research may help in the fight against ... detect tiny quantities of explosives with the use of ... journal Sensors and Actuators B: Chemical , the ... detect explosives in concentrations as low as 6.3 ppm ... only a few minutes. , "Traditionally explosives detection has ...
(Date:7/10/2014)... the journal PNAS (Proceedings of the National Academy ... and sleep deprivation have a significant effect on our ... the best time of day to test for diseases ... medicines effectively. , Researchers from the University of Surrey ... links between sleep deprivation, body clock disruption and metabolism, ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2Time of day crucial to accurately test for diseases, new research finds 2
... and Jack Ballantyne, Forensic Biochemistry/Genetics Professor at University of ... join ... GenVault Corporation today,announces that two leading industry experts, ... its Scientific Advisory Board. Dr.,Lai-Goldman is currently the Chief ...
... primer, now in its 3rd edition., ... the third,edition of Building Biotechnology, the definitive ... business courses. This new,edition adds over 100 ... new,and updated figures and tables, and many ...
... -- Record consolidated revenues of $14.9 million -- Record ... $2.3 million - 49% growth ... credit facility - expands capital resources, -- Reported MIS procedure times of 60 minutes and hospital ... days or ...
Cached Biology Technology:GenVault Expands Scientific Advisory Board 2GenVault Expands Scientific Advisory Board 3New Book on the Business of Biotechnology 2AtriCure Reports Record Second Quarter 2008 Financial Results 2AtriCure Reports Record Second Quarter 2008 Financial Results 3AtriCure Reports Record Second Quarter 2008 Financial Results 4AtriCure Reports Record Second Quarter 2008 Financial Results 5AtriCure Reports Record Second Quarter 2008 Financial Results 6AtriCure Reports Record Second Quarter 2008 Financial Results 7AtriCure Reports Record Second Quarter 2008 Financial Results 8
(Date:7/11/2014)... division of the striatum is also involved in ... of substance P in the striatal marginal division ... his team, College of Biophotonics, South China Normal ... P receptor, neurokinin 1 was highly expressed in ... rats. Unilateral or bilateral injection of an antisense ...
(Date:7/11/2014)... Brazil- In the brains of all vertebrates, information ... an electric or chemical signal to be passed ... which are the most abundant type of synapse, ... is crucial for learning, memory, perception and cognition, ... critical for brain function. For instance, every ...
(Date:7/10/2014)... 2014 Smart technology emphasis grows in ... improved security: NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. (NASDAQ: ... Apple Inc. (NASDAQ: AAPL ), Visa Inc. (NYSE: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on ... second series of 30 second spots on CNBC for its ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5
... Mass.--MIT engineers and colleagues have built a new tissue ... transplanted into the knees and other joints. The ... injuries and other cartilage damage, such as arthritis, says ... Science and Engineering and co-leader of the research team ...
... of Medical Genetics (ACMG) has issued a new Position ... Spots. In May 2006, ACMG recommended that all newborns ... Tremendous progress has been made in,implementing broader and more ... thousands of babies, lives have been saved or have ...
... of how the elevated glucose levels that occur in ... for blocking the destruction, Medical College of Georgia researchers ... vessels to relax resulted from increased activity of a ... Dr. Rita C.Tostes, physiologist in the MCG School of ...
Cached Biology News:MIT: New tissue scaffold regrows cartilage and bone 2American College of Medical Genetics affirms importance of newborn screening dried blood spots 2New evidence of how high glucose damages blood vessels could lead to new treatments 2
... is formulated specifically for Alkaline Phosphatase conjugates. ... of activity for both the enzyme and ... dilution. This product has been chemically ... customer a longer shelf life, resistance to ...
... Mouse monoclonal [3D12] to Lambda Free ... Mixture of light chains of human ... for independent constantly expressed epitope of ... dimer forms of free lambda chains ...
... The SDSaway reagent is a valuable ... samples. The presence of SDS in ... the tightly bound SDS-protein complex, inhibits enzymatic ... and presents as a contaminant in mass ...
... ALH 4000 workstation is the simplest, easiest-to-use ... introduce automated liquid handling capabilities,into their labs, ... to support routine applications on a separate ... walk-away automation even when you have ...
Biology Products: